医学临床研究
醫學臨床研究
의학림상연구
JOURNAL OF CLINICAL RESEARCH
2014年
4期
696-698
,共3页
结肠炎 ,溃疡性/药物疗法%氨水杨酸/投药和剂量%胶囊
結腸炎 ,潰瘍性/藥物療法%氨水楊痠/投藥和劑量%膠囊
결장염 ,궤양성/약물요법%안수양산/투약화제량%효낭
Colitis,Ulcerative/DT%Mesalamine/AD%Capsules
【目的】从临床表现、肠镜及肠道菌群变化多方面对双歧杆菌三联活菌胶囊联合美沙拉嗪治疗溃疡性结肠炎疗效进行评价。【方法】选择本院92例溃疡性结肠炎采用数字表随机法分为两组,每组46例。对照组给予美沙拉嗪治疗,观察组在对照组基础上加用双歧杆菌三联活菌胶囊治疗,比较两组治疗前后临床症状总积分、肠道菌群、肠镜分级变化。【结果】观察组总有效率89.13%;对照组总有效率58.7%,观察组疗效明显优于对照组(P <0.05)。观察组治疗后症状评分、肠镜评分降低幅度大于对照组(P <0.05)。治疗后观察组乳酸杆菌、双歧杆菌数量明显增加,大肠杆菌、肠球菌数量明显下降( P <0.05)。【结论】双歧杆菌三联活菌胶囊联合美沙拉嗪治疗溃疡性结肠炎有助于患者肠道菌群的平衡,从而达到抑制炎症的目的,显著提高疗效。
【目的】從臨床錶現、腸鏡及腸道菌群變化多方麵對雙歧桿菌三聯活菌膠囊聯閤美沙拉嗪治療潰瘍性結腸炎療效進行評價。【方法】選擇本院92例潰瘍性結腸炎採用數字錶隨機法分為兩組,每組46例。對照組給予美沙拉嗪治療,觀察組在對照組基礎上加用雙歧桿菌三聯活菌膠囊治療,比較兩組治療前後臨床癥狀總積分、腸道菌群、腸鏡分級變化。【結果】觀察組總有效率89.13%;對照組總有效率58.7%,觀察組療效明顯優于對照組(P <0.05)。觀察組治療後癥狀評分、腸鏡評分降低幅度大于對照組(P <0.05)。治療後觀察組乳痠桿菌、雙歧桿菌數量明顯增加,大腸桿菌、腸毬菌數量明顯下降( P <0.05)。【結論】雙歧桿菌三聯活菌膠囊聯閤美沙拉嗪治療潰瘍性結腸炎有助于患者腸道菌群的平衡,從而達到抑製炎癥的目的,顯著提高療效。
【목적】종림상표현、장경급장도균군변화다방면대쌍기간균삼련활균효낭연합미사랍진치료궤양성결장염료효진행평개。【방법】선택본원92례궤양성결장염채용수자표수궤법분위량조,매조46례。대조조급여미사랍진치료,관찰조재대조조기출상가용쌍기간균삼련활균효낭치료,비교량조치료전후림상증상총적분、장도균군、장경분급변화。【결과】관찰조총유효솔89.13%;대조조총유효솔58.7%,관찰조료효명현우우대조조(P <0.05)。관찰조치료후증상평분、장경평분강저폭도대우대조조(P <0.05)。치료후관찰조유산간균、쌍기간균수량명현증가,대장간균、장구균수량명현하강( P <0.05)。【결론】쌍기간균삼련활균효낭연합미사랍진치료궤양성결장염유조우환자장도균군적평형,종이체도억제염증적목적,현저제고료효。
[Objective] To evaluate the efficacy of bifid triple viable capsule combined with mesalazine in the treatment of ulcerative colitis in many aspects of clinical manifestation ,colonoscopy and the changes of intestinal flora .[Methods]Totally 92 patients with ulcerative colitis patients in our hospital were divided into two groups by random digital table classification .The control group was given mesalazine only ,while the observation group was given mesalazine combined with bifid triple viable capsule .Clinical symptom scores ,intestinal flora and colonosco-py scores before and after the treatment were compared between two groups .[Results]The total effective rate of the observation group and control group was 89 .13% and 58 .7% ,respectively .The efficacy of observation group was obviously better than the control group ( P <0 .05) .After the treatment ,the decreasing degree of symptom scores and colonoscopy scores in observation group was larger than that in control group ( P<0 .05) .The number of lactobacillus and bifid bacterium in observation group after treatment were increased obviously ,but the number of Escherichia coli and Enterococcus were decreased obviously ( P<0 .05) .[Conclusion]Bifid triple viable capsule combined with mesalazine is benefit for the balance of intestinal flora ,and thus can inhibit the inflammation and significantly improve the curative effect .